Clinical Trials
4
Active:1
Completed:1
Trial Phases
2 Phases
Early Phase 1:1
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Early Phase 1
1 (25.0%)Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Salarius Pharmaceuticals, LLC
- Target Recruit Count
- 72
- Registration Number
- NCT05979857
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
Phase 1
- Conditions
- Ewing SarcomaLow Grade Fibromyxoid SarcomaExtraskeletal Myxoid ChondrosarcomaDesmoplastic Small Round Cell TumorClear Cell SarcomaMyxoid LiposarcomaAngiomatoid Fibrous HistiocytomaSclerosing Epithelioid FibrosarcomaMyoepithelial Tumor
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Salarius Pharmaceuticals, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT05266196
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Salarius Pharmaceuticals, LLC
- Target Recruit Count
- 23
- Registration Number
- NCT03895684
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸Sarcoma Oncology Research Center, Santa Monica, California, United States
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Phase 1
Active, not recruiting
- Conditions
- Ewing SarcomaClear Cell SarcomaMyoepithelial TumorDesmoplastic Small Round Cell TumorAngiomatoid Fibrous HistiocytomaMyxoid LiposarcomaSarcoma,Soft TissueExtraskeletal Myxoid ChondrosarcomaSclerosing Epithelioid FibrosarcomaFibromyxoid Tumor
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Salarius Pharmaceuticals, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT03600649
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Sarcoma Oncology Research Center, Santa Monica, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
News
No news found